31 provinces across the country have implemented centralized insulin procurement, how much does it r

It can reduce the economic burden by about half.

All 31 provinces across the country have been implemented, and the implementation of insulin and finance can reduce about half of the economic burden of sugar. Before the implementation of insulin centralized procurement, there was often a monthly cost of buying insulin, about seven or eight hundred yuan after the substrate, they only need to spend three or four hundred yuan per month to meet the body's need for insulin, which can save about half of the cost and reduce half of the economic burden, which is definitely good news for sugar friends with lower incomes.

After the centralized procurement of insulin, the financial burden of sugar friends has decreased, and the control of the disease has become more concerned. Although they know that needles are disposable and disposable, in order to save costs, they will still use a needle for several days in a row, thinking that this can save some money, but after the cost of insulin collection, they will no longer feel sorry for the investment of needles, and will use the needles once, which can better ensure safety.

Before the centralized procurement of insulin, some sugar friends were not active in monitoring blood sugar, because they were reluctant to use test strips and reluctant to buy new equipment, so they could only use the test pen of the blood glucose meter to prick their fingers repeatedly, resulting in a thick layer of old skin on their fingers, and they were covered with pinholes, which looked a little sad, but after the implementation of centralized insulin procurement, they saved the cost of purchasing insulin, and they freed up funds to buy continuous blood glucose meters, so that they could observe blood sugar more intuitively in the future and find their own blood sugar changes.

After the implementation of centralized procurement of insulin, it not only reduces the financial burden of sugar friends, but also allows sugar friends to better monitor their conditions and cooperate with doctors. In the past, insulin was high, and many people would cut corners after getting diabetes, and the doctors who did not cooperate with the doctor asked them to use insulin every day, but they would secretly stop using it after they felt that their blood sugar was stable, which would lead to repeated increases in blood sugar and aggravate the condition. After the centralized insulin procurement** decreases, their economic burden is reduced, and they can better cooperate with the doctor to use insulin on time, which is of great benefit to the stability and control of the disease.

It relieves a particularly large financial burden for "sugar friends", which can bring great convenience to everyone, and can also allow them to have a better body.

It has reduced a lot of financial burden, they no longer have to pay out of their own pockets for collection, and they can also be reimbursed part of the money for medical treatment.

Diabetes mellitus is one of the most common metabolic diseases with abnormal blood sugar levels in China, and the occurrence of diabetes is caused by insufficient or non-secretion of insulin and resistance to insulin, among which the number of patients with diabetes caused by insufficient insulin secretion is the largest. Therefore, the most effective measure for diabetes is to inject insulin to lower blood sugar. Although there are differences between different brands of insulin, it is generally a relatively high level, which has caused a more serious burden on many patients, so China began to implement insulin centralized procurement measures, and after the full implementation of this measure, the average ** decline has reached 48%, so why is the ** fluctuation so big?

This is because the centralized procurement of insulin is made by the state to buy insulin in large quantities, which is equivalent to the highest insulin, and will negotiate with relevant brands, so it can strive for the largest price and reduce the burden on patients. Nowadays, many diabetic patients in China will choose whether to inject insulin premature fibrillation according to the degree of their condition, and if they do not reach a level that seriously affects their lives, they will not choose to inject insulin, which will cause serious damage to other organs of the human body in the long run.

Therefore, insulin needs to be injected for a long time, and the implementation of this policy will help patients maintain the continuity of medication. Insulin is the only hormone in the body that can lower blood sugar levels, so once deficient, the body's blood sugar levels will be in a high and uncontrollable state, and diabetes will occur.

Now the most effective measure for diabetes is insulin injection, insulin is now synthesized after people's research, compared with the beginning, ** has been in a downward trend. However, there is also a situation where different brands of insulin have different effects on different patients, and patients may not be suitable if they change insulin, so many people may still have difficulty in taking drugs.

Because there will be professionals to negotiate for us, they will use the market prospect as the basis for negotiation, and talk about the lowest level of drugs.

Because the technology is mature and can be mass-produced, the ** fluctuation is relatively large.

It is because the state has allocated a ** to support this cause, in order to reduce the burden of the people, so the ** has dropped so much.

Shanghai Pharmaceutical Sunshine Procurement Network issued the "Notice on Doing a Good Job in the Sixth Batch of Centralized Procurement of Drugs in the City Organized by the State", announcing that Shanghai will implement the results of the sixth batch of national centralized procurement of Zen and filial piety from now on. Up to now, 31 provinces across the country have implemented centralized insulin procurement, which is expected to save about 9 billion yuan in insulin costs every year after centralized procurement, and will further reduce the drug burden of more than 10 million patients who need long-term or even lifelong insulin injections. This news is undoubtedly great news for people who need insulin, with an average price reduction of 48%, what is this concept?

It's equivalent to buying two pills for the same amount of money. For patients, it's just spring coming. In addition to the happiness of patients, there is a lot of news worth paying attention to, that is, what changes will occur in this 100-billion-level market?

Let's analyze this topic together. <>

Judging from the news this time, the special collection varieties of insulin include the mainstream second and third generations, and the insulin collection varieties are divided into a total of 6 procurement groups, such as meal human insulin, basic human insulin and premixed human insulin. And 11 companies were also selected, so the question is, will these 11 companies carve up the 100 billion market? I think so.

After all, from the perspective of the competitive landscape, the fierce competition in this market is quite exaggerated, and the demand for diabetes drugs in China is particularly large. <>

This has led to the fierce competition in the market, and this time the insulin collection has been fully implemented and the price has been directly reduced, and 48% of the measures will make this 100 billion level market undergo earth-shaking changes. Personally, I don't think it will bring the economy down, but it will also increase consumption in this area. It is very likely that it will not be a 100-billion-level market, but a trillion-level market.

But no matter which aspect you look at, this is a very good introduction for patients, and I think such a policy is also very beneficial. <>

The price reduction of this centralized procurement is larger, which will help domestic leading enterprises seize the market, and the industry competition pattern is expected to be optimized. The successful centralized procurement of insulin marks that China has officially entered the stage of biological drug collection.

I think that if we do this, it will lead to a very significant change in the market, after all, the impact of these insulins on diabetics is very positive, and there are also gods that are beneficial to their health will also strengthen the prevention and treatment of diabetes.